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Background and purpose: Surveillance studies evaluating antimicrobial susceptibilities are of great value in
preventing the spread of resistant pathogens by elucidating the trend of resistance in commonly used antibiotics
and as a consequence providing information for prescribing the most appropriate agent. This study is a
longitudinal antimicrobial resistance surveillance study designed to evaluate the trend in antimicrobial resistance to
gram negative microorganisms from 2007 to 2010.
Method: During a four-year period (2007–2010) isolates derived from all patients admitted to infectious diseases
ward of Imam Khomeini Hospital, the major referral center for infectious disease in Iran with the highest admission
rates, were evaluated. Based on disk diffusion method and zone of inhibition size, the microorganism was regarded
as to be sensitive, resistant or has intermediate susceptibility to the antimicrobial agents.
Results: The widest spread Gram-negative microorganism in all of isolates taken together in our study was E.coli
(30%) followed by Stenotrophomonas maltophilia in 28.6% and Enterobacter spp. in 11.9%, respectively. The
susceptibility to amikacin, imipenem, piperacillin/tazobactam, and nitrofurantoin was equal or above 50% for all
microorganisms over four years. However, the susceptibility to ampicillin, ampicillin/sulbactam, cefotaxim, and
ceftriaxone was less than 50% in derived isolates during the study period.
Conclusion: In conclusion, the finding of the present study revealed that resistance rate to common antimicrobial
agents in Iran is growing and isolates were susceptible mostly to broad-spectrum antibiotics including imipenem
and piperacillin/tazobactam.
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Antibiotic resistance is a critical challenge for infective
diseases management around the word [1-3]. Infection
with a resistant strain has been associated to higher rate
of morbidity and mortality as well as prolonged length
of hospital and intensive care unit stay and increased
expenses for the healthcare systems [3,4].
Surveillance studies evaluating antimicrobial susceptibil-
ities are of great value in providing information for prescrib-
ing the most appropriate agent [5]. These studies could be* Correspondence: khalilih@tums.ac.ir
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reproduction in any medium, provided the orused as a guide in antimicrobial usage policies in order to
halt the expansion of microorganism resistance [6-10].
Although there are few reports on the antibiotic resist-
ance in Iran, many of them are simple point-in-time
prevalence studies or evaluated pathogens involved in a
specific infectious disease [11-14]. Present evaluation is a
longitudinal antimicrobial resistance surveillance study
designed to evaluate the trend in antimicrobial resistance
to nosocomial origin gram negative microorganisms, from
2007 to 2010.Methods
During a four-year period (2007–2010) isolates bio-
logical samples from all patients admitted to Infectioustd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Khalili et al. DARU Journal of Pharmaceutical Sciences 2012, 20:28 Page 2 of 12
http://www.darujps.com/content/20/1/28Diseases Ward of Imam Khomeini Hospital Complex,
the major referral center for infectious disease in Iran
with the highest admission rates, were evaluated. The
Institutional Review Board (IRB) and the Medical Ethics
Committee of the hospital approved the study.
Isolates were sent to a central laboratory of the hos-
pital for identification and antimicrobial susceptibility
testing by Kirby – Bauer disc diffusion method. Based
on zone of inhibition size the microorganism was
regarded as to be sensitive, resistant or intermediate sus-
ceptibility to the antimicrobial agent. Microorganisms’
susceptibilities were investigated against those antimi-
crobials of clinical utility for the treatment of infections
caused by susceptible Gram- negative bacteria available
in the hospital. β-lactams such as ampicillin and pipera-
cillin from penicillin class; cephalosporins including
cefixime, cefotaxim, ceftazidim, ceftriaxone, cefepime;
and the carbapenems such as imipenem were among
evaluated antimicrobials. Combinations of penicillins
with β-lactamase inhibitors including piperacillin-
tazobactam and ampicillin-sulbactam, fluroquinolones
such as ciprofloxacin, aminoglycosides including amika-
cin and gentamicin, nitrofurantoin and cotrimoxazole
were those studied for antimicrobial resistance pattern
in this surveillance. The trend in this pattern over four
years was reviewed and reported.Results
In a four-year period from 2007 to 2010, 1745 isolates
were sent to the central library of the hospital, from
those 983 (56.3%) were confirmed to be Gram-negative
pathogens. The most frequent specimen sources were
blood (46.2%) followed by the urine (27%), and wound
(13.7. The most wide spread Gram-negative microorgan-
ism in all of isolates taken together in our study was E.
coli (30%) followed by Stenotrophomonas maltophilia in
28.6% and Enterobacter spp. in 11.9%, respectively. The
frequency of microorganisms in terms of the derived iso-
lates is shown in Table 1.Table 1 Frequency of Gram-negative microorganisms
according to the origins of specimen resource
Microorganism Blood Urine Wound Other Total
E.Coli 14 201 40 30 285
Stenotrophomonas sp. 278 0 1 2 281
Enterobacter 64 42 5 6 117
Pseudomona 21 25 25 13 84
Acinetobacter 29 22 10 13 74
Kelebsiela 18 32 6 8 64
Proteus 2 9 20 11 42
Citrobacter 3 22 6 5 36
Total 429 353 113 88 983The overall susceptibility of the specimens to anti-
microbial agents did not remain the same over four
years. For some of antimicrobial agents, the percentage
of susceptible microorganisms was increased including
ciprofloxacin (44.2 to 68.4%), piperacillin(33.3 to 66.7%)
and piperacillin/tazobactam (77.8 to 89.5%). In contrast
the susceptibility of nosocomial pathogens was reduced
against nitrofurantoin (75.9 to 56%) in a four-year
period. The susceptibility of microorganisms against all
other antimicrobial agents showed non-steady pattern.
The susceptibility to amikacin, imipenem, piperacillin/
tazobactam, and nitrofurantoin was equal or above 50%
for microorganisms all over four years. However, the
susceptibility to ampicillin, ampicillin/sulbactam, cefo-
taxim, and ceftriaxone was less than 50% in derived iso-
lates during the study period. The resistance rate of
microorganism to Cefepime was increased in 2007–2008
while the susceptibilities were enhanced in 2009–2010.
Comparison of the trend of resistance pattern of isolated
bacteria of nosocomial originas well as the rate of fre-
quency of each pathogen was illustrated in Table 2.
Regarding the microorganisms, the most frequent resis-
tances were seen in Acientobacter followed by Citrobac-
ter with 50–73.7% and 58.3-65.8% resistant isolates,
respectively. In contrast, Enterobcter was the most sus-
ceptible microorganism with resistance rate of 25.6-
29.5% in the study period. The switches in the percent
of resistant microorganism were not the same for all of
the pathogens (Table 3). Proteus resistance was
decreased in four-year period from 43.9% to 6.7% against
all of the antibiotics taken together. Acinetobacter resist-
ance to ciprofloxacin was increased whereas Enterobac-
ter resistance rate to Gentamicin and Ciprofloxacin and
E.coli resistance to Ceftazidim was decreased in four-
year period. The number of resistant Entrobacter isolates
to Cefixim was increased. From 2008 to 2010 the
susceptibility rate of Acinetobacter against Ampicillin/
sulbactam was reduced.
Discussion
Antimicrobial resistance is a widespread problem that
health care providers are encountered with all over the
world. Determining the specific pattern of antibiotic re-
sistance especially in infectious diseases wards of main
hospitals in every country is of great value for control-
ling the rate of increasing resistance as well as helping in
empirical treatment. Since Imam Khomeini hospital
Complex is the main center for infectious diseases in
Iran with the highest admission rates, we can say that a
serious problem of antimicrobial resistance to commonly
used antibiotics exists among different isolates in Iran.
The most frequent isolated pathogen from all speci-
mens taken together was E. coli followed by S. maltophi-
lia and Enterobacter sp. with E. coli being the major




Sensitive; n (%) Intermediate; n (%) Resistant; n (%)
2007 2008 2009 2010 2007 2008 2009 2010 2007 2008 2009 2010
Amikacin
Acinetobacter 8 13 7 1 1 0 0 1 9 6 9 8
Citrobacter 4 5 11 N/A 1 0 0 N/ 7 7 20 N/
E.Coli 62 85 53 26 2 0 0 A 10 8 16 A
Enterobacter 20 34 25 13 0 0 1 0 1 1 3 4
Kelebsiella 13 10 12 4 2 0 0 0 7 1 6 1
Proteus spp. 8 4 13 5 0 0 0 1 3 0 1 1
Pseudomonas sp. 9 18 12 11 0 0 0 0 2 3 11 6
Stenotrophomonas sp. 9 40 83 25 2 1 0 0 11 31 29 24
Total 133 (69.6%) 209 (78.3%) 216 (69.2%) 85 (64.4%) 8 (4.2%) 1 (0.3%) 1 (0.3%) 1 3 (2.3%) 50 (26.2%) 57 (21.3%) 95 (30.4%) 44 (33.3%)
Ampicillin/sulbactam
Acinetobacter 1 5 11 3 0 0 0 0 3 3 10 5
E.Coli 3 6 15 7 0 0 2 1 2 12 49 15
Enterobacter 5 3 9 4 0 0 1 0 0 5 15 1
Kelebsiella 0 1 5 1 0 0 0 0 3 1 11 4
Proteus spp. 1 2 11 5 0 0 0 0 0 0 4 0
Pseudomonas sp. 0 0 3 0 0 0 0 0 2 4 20 14
Stenotrophomonas sp. 1 1 1 1 1 0 0 1 9 19 5 2
Total 11 (35.5%) 18 (29%) 55 (32%) 21 (32.8%) 1 (3.2%) 0 (0) 3 (1.7%) 2 (3.1%) 19 (61.3%) 44 (71%) 114 (66.3%) 41 (64.1%)
Ampicillin
E.Coli 0 0 1 1 0 0 0 0 2 22 25 0
Enterobacter 0 0 2 0 0 0 0 0 1 5 4 2
Total 0 (0) 0 (0) 3 (9.4%) 1 (33.3%) 0 (0) 0 (0) 0 (0) 0 (0) 3 (100%) 27 (100%) 29 (90.6%) 2 (66.7%)
Cotrimoxazole
Acinetobacter 7 6 5 1 0 0 0 0 14 10 13 8
Citrobacter 1 2 3 1 0 0 0 0 6 6 13 1
E.Coli 21 19 24 8 0 0 1 0 49 59 47 20
Enterobacter 12 24 21 8 0 0 0 0 11 13 7 4
Kelebsiella 6 5 7 2 0 0 0 0 17 3 12 4
Proteus spp. 4 2 4 3 0 1 0 0 7 3 9 1
Pseudomonas sp. 0 7 4 2 0 0 0 0 13 11 20 14


















Table 2 Comparison of resistance pattern of isolated bacteria of nosocomial origin in four-year period (Continued)
Total 73 (38.2%) 143 (57%) 173 (58.2%) 60 (49.2%) 0 (0) 1 (0.4%) 1 (0.4%) 0 (0) 118 (61.8%) 107 (42.6%) 123 (41.4%) 62 (51.8%)
Cefepim
E.Coli 3 4 7 2 0 0 0 0 3 3 5 1
Enterobacter 0 4 5 1 0 0 0 0 1 6 2 1
Proteus spp. 1 0 4 1 0 1 0 0 1 2 0 0
Pseudomonas sp. 0 0 2 1 0 0 0 0 1 8 4 3
Total 4 (40%) 8 (28.6%) 18 (62.1%) 5 (50%) 0 (0) 1 (3.6%) 0 (0) 0 (0) 6 (60%) 19 (67.9%) 11 (37.9%) 5 (50%)
Cefixime
Acinetobacter 0 0 1 0 0 0 0 0 4 7 3 1
E.Coli 3 2 2 0 0 0 0 0 11 10 0 1
Enterobacter 3 6 1 0 1 2 0 1 3 11 2 4
Proteus spp. 1 0 4 1 0 1 0 0 1 2 0 0
Pseudomonas sp. 0 0 2 1 0 0 0 0 1 8 4 3
Total 7 (25%) 8 (40%) 10 (52.6%) 2 (16.7%) 1 (3.6%) 3 (15%) 0 (0) 1 (8.3%) 20 (71.4%) 9 (45%) 9 (47.4%) 9 (75%)
Cefotaxim
Acinetobacter 1 1 0 1 0 0 0 0 4 3 5 1
Citrobacter 0 1 0 1 0 0 0 0 5 1 2 1
Pseudomonas sp. 0 1 0 1 0 0 0 0 4 1 4 1
Stenotrophomonas sp. 1 0 0 0 2 0 0 0 5 8 3 1
Total 2 (10%) 3 (18.7%) 0 (0) 3 (42.8%) 0 (0) 0 (0) 0 (0) 0 (0) 18 (90%) 13 (91.3%) 14 (100%) 4 (57.2%)
Ceftazidim
Acinetobacter 0 0 2 2 0 0 0 0 4 8 5 2
E.Coli 3 3 7 15 0 0 1 0 4 16 43 6
Enterobacter 5 1 12 7 0 0 1 0 0 9 8 4
Kelebsiella 2 1 6 0 0 1 0 0 0 4 7 2
Proteus spp. 2 0 8 4 0 1 0 0 2 3 1 0
Pseudomonas sp. 2 0 4 3 0 0 0 0 1 12 12 4
Stenotrophomonas sp. 0 5 1 2 0 1 0 0 9 31 1 6
Total 14 (41.2%) 10 (10.4%) 40 (33.6%) 33 (57.9%) 0 (0) 3 (3.1%) 2 (1.7%) 0 (0) 20 (58.8%) 83 (86.4%) 77 (64.7%) 24 (42.1%)
Ciprofloxacin
Acinetobacter 9 4 7 1 0 1 0 0 8 8 13 6
E.Coli 19 26 24 13 0 0 0 0 44 51 49 18
Enterobacter 12 18 24 8 0 0 0 0 8 7 8 2
Kelebsiella 6 4 10 4 2 0 0 0 20 7 20 7


















Table 2 Comparison of resistance pattern of isolated bacteria of nosocomial origin in four-year period (Continued)
Pseudomonas sp. 8 6 10 12 0 1 1 0 2 9 14 3
Stenotrophomonas sp. 15 39 109 45 0 0 0 0 3 0 0 1
Total 73 (44.2%) 99 (53.2%) 192 (63.2%) 80 (68.4%) 2 (1.2%) 2 (1.1%) 1 (0.3%) 0 (0) 90 (54.5%) 85 (45.7%) 111 (36.5%) 37 (31.6%)
Gentamicin
Acinetobacter 5 9 4 1 1 0 0 0 9 2 6 5
E.Coli 18 49 24 12 1 1 2 0 32 35 36 8
Enterobacter 9 23 21 5 0 0 1 0 4 6 5 1
Kelebsiella 7 4 10 3 0 0 0 0 11 5 5 3
Proteus spp. 2 5 8 1 1 0 0 0 4 0 0 1
Pseudomonas sp. 5 12 1 4 0 0 0 0 3 7 10 2
Stenotrophomonas sp. 8 31 3 2 1 2 0 0 4 9 3 0
Total 54 (43%) 133 (66.5%) 71 (51.1%) 28 (58.3%) 4 (3%) 3 (1.5%) 3 (2.2%) 0 (0%) 67 (54%) 64 (32%) 65 (46.8%) 20 (51.7%)
Imipenem
Acinetobacter 8 15 20 7 0 3 0 1 4 0 1 3
E.Coli 25 47 77 29 0 0 0 0 0 0 0 2
Enterobacter 12 30 31 13 0 0 0 0 0 0 0 1
Kelebsiella 10 8 19 8 0 0 0 0 0 0 0 0
Proteus spp. 7 6 17 6 0 0 0 0 0 0 0 0
Pseudomonas sp. 9 22 26 15 0 0 0 0 1 0 1 1
Stenotrophomona s sp. 2 10 2 2 0 1 1 0 20 49 7 9
Total 73 (74.5%) 132 (71.3%) 192 (95%) 80 (82.5%) 0 (0) 4 (2.2%) 1 (0.5%) 1 (1%) 25 (25.5%) 49 (26.5%) 9 (4.5%) 16 (16.5%)
Nitrofurantoin
Acinetobacter 2 2 1 0 0 0 0 0 5 3 0 2
E.Coli 31 68 39 10 1 1 0 0 2 11 11 1
Enterobacter 4 8 8 1 1 1 0 0 1 8 3 0
Kelebsiella 5 2 5 3 0 0 1 0 1 3 3 2
Proteus spp. 1 1 0 0 0 0 0 0 2 0 1 1
Pseudomonas sp. 1 0 0 0 0 0 1 0 1 8 3 5
Total 44 (75.9%) 81 (69.8%) 53 (69.7%) 14 (56%) 2 (3.5%) 2 (1.7%) 2 (2.6%) 0 (0) 12 (20.7%) 33 (28.5%) 21 (27.6%) 11 (44%)
Piperacillin
Acinetobacter 2 4 N/A 0 1 0 N/A 0 5 3 N/A 3
E.Coli 2 0 N/A 1 0 0 N/A 0 18 4 N/A 0
Enterobacter 9 14 N/A 6 0 0 N/A 0 2 4 N/A 1
Kelebsiella 3 2 N/A 1 0 0 N/A 0 6 4 N/A 0


















Table 2 Comparison of resistance pattern of isolated bacteria of nosocomial origin in four-year period (Continued)
Ceftriaxone
Acinetobacter 1 6 4 0 0 0 0 0 15 13 10 9
E.Coli 17 40 16 13 0 1 1 0 51 50 55 17
Enterobacter 9 19 19 10 0 0 1 0 9 12 8 5
Kelebsiella 3 3 5 2 1 0 0 0 16 6 13 4
Proteus spp. 5 3 14 6 0 0 0 0 5 0 2 0
Pseudomonas sp. 2 2 4 5 0 4 1 0 7 13 19 8
Stenotrophomonas sp. 1 5 3 2 0 0 1 0 16 65 91 49
Total 39 (24.5%) 78 (32.2%) 65 (24.3%) 38 (29.2%) 1 (0.6%) 5 (2.1%) 4 (1.5%) 0 (0) 119 (74.8%) 159 (65.7%) 198 (74.2%) 92 (70.8%)
Piperacillin/tazobactam
Acinetobacter 2 1 12 3 0 0 0 0 1 1 5 0
E.Coli 1 3 22 18 0 0 0 0 0 1 0 0
Proteus spp. 1 1 12 5 0 0 0 0 0 0 0 3
Pseudomonas sp. 1 3 13 6 0 0 0 1 1 0 4 0
Stenotrophomonas sp. 2 3 5 2 0 0 0 0 0 1 1 0






















Sensitive; n (%) Intermediate; n (%) Resistant; n (%)
2007 2008 2009 2010 2007 2008 2009 2010 2007 2008 2009 2010
Acinetobacter
Amikacin 8 13 7 1 1 0 0 1 9 6 9 8
Ampicillin/sulbactam 1 5 11 3 0 0 0 0 4 8 21 8
Cotrimoxazole 7 6 5 1 0 0 0 0 14 10 13 8
Cefixime 0 0 1 0 0 0 0 0 4 7 3 1
Cefotaxime 1 1 0 1 0 0 0 0 4 3 5 1
Ceftazidim 0 2 2 0 0 0 0 0 4 10 7 2
Ciprofloxacin 9 4 7 1 0 1 0 0 8 8 13 6
Gentamicin 5 9 4 1 1 0 0 0 9 2 6 5
Imipenem 8 15 20 7 0 3 0 1 4 0 1 3
Nitrofurantoine 2 2 1 0 0 0 0 0 5 3 0 2
Piperacillin 2 4 N/A 0 1 0 N/A 0 5 3 N/A 3
Ceftriaxone 1 6 4 0 0 0 0 0 15 13 10 9
Piperacillin/ tazobactam 2 1 12 3 0 0 0 0 1 1 5 0
Total 46 (34.1%) 68 (45.9%) 74 (44.3%) 18 (23.7%) 3 (2.2%) 4 (2.7%) 0 (0) 2 (2.6%) 86 (63.7%) 74 (50%) 93 (55.7%) 56 (73.7%)
Citrobacter
Amikacin 4 5 11 N/A 1 0 0 N/A 2 2 9 N/A
Cotrimoxazole 1 2 3 N/A 0 0 0 6 6 13 N/A
Cefixime 0 1 0 N/A 0 0 0 N/A 1 1 1 N/A
Ciprofloxacin 2 3 3 N/A 0 0 0 6 4 21 N/A
Gentamicin 1 5 4 N/A 0 0 0 N/A 5 1 11 N/A
Imipenem 4 3 20 N/A 0 0 0 N/A 0 0 0 N/A
Ceftriaxone 0 1 3 N/A 0 0 1 N/A 5 14 16 N/A
Total 12 (31.6%) 20 (41.7%) 44 (37.9%) N/A 1 (2.6%) 0 (0) 1 (0.9%) N/A 25 (65.8%) 28 (58.3%) 71 (61.2%) N/A
E. coli
Amikacin 62 85 53 26 2 0 0 0 10 8 16 4
Ampicillin/sulbactam 3 6 15 7 0 0 2 1 2 12 49 15
Ampicillin 0 0 1 1 0 0 0 0 2 22 26 1
Cotrimoxazole 21 19 24 8 0 0 1 0 49 59 47 20
Cefepime 3 4 7 2 0 0 0 0 3 23 5 1
Cefixime 3 2 2 0 0 0 0 0 11 10 0 1
Ceftazidim 3 3 7 15 0 0 1 0 4 16 43 6


















Table 3 Comparison of resistance pattern of isolated bacteria against different antimicrobial agents in four-year period (Continued)
Gentamicin 18 49 24 12 1 1 2 0 32 35 26 8
Imipenem 25 47 77 29 0 0 0 0 0 0 0 2
Nitrofurantoine 31 68 39 10 1 1 0 0 2 11 11 1
Ceftriaxone 17 40 16 13 0 1 1 0 51 50 55 17
Piperacillin/ tazobactam 1 3 22 18 0 1 1 0 0 1 0 0
Total 206 (49.1%) 352 (53.8%) 311 (48.1%) 154 (61.8%) 4 (0.9%) 4 (0.6%) 8 (1.2%) 1 (0.4%) 210 (50%) 298 (45.6%) 327 (50.6%) 94 (37.7%)
Enterobacter 20 34 25 13 0 0 1 0 1 1 3 1
Amikacin 5 3 9 4 0 0 1 0 0 5 15 1
Ampicillin/sulbactam 0 0 2 0 0 0 0 0 1 5 4 2
Ampicillin 12 24 21 8 0 0 0 0 11 13 7 4
Cotrimoxazole 0 4 5 1 0 0 0 0 1 6 2 1
Cefepime 3 6 1 0 1 2 0 1 3 11 2 4
Cefixime 5 11 12 7 0 0 1 0 0 9 8 4
Ceftazidim 12 18 24 8 0 0 0 0 8 7 8 2
Ciprofloxacin 9 23 21 5 0 0 1 0 4 6 5 1
Gentamicin 12 30 31 13 0 0 0 0 0 0 0 1
Imipenem 4 8 8 1 1 1 0 0 1 8 3 0
Nitrofurantoine 9 19 19 10 0 0 1 0 9 12 8 5
Ceftriaxone
Total 91 (68.9%) 180 (67.7%) 178 (72.3%) 70 (72.2%) 2 (1.5%) 3 (1.1%) 5 (20.3%) 1 (0.1%) 39 (29.5%) 83 (31.2%) 63 (25.6%) 26 (26.8%)
Kelebsiella
Amikacin 13 10 12 4 2 0 0 1 7 1 6 1
Ampicillin/sulbactam 0 1 5 1 0 0 0 0 3 1 11 4
Cotrimoxazole 6 5 7 2 0 0 0 0 17 3 12 4
Cefixime 1 3 1 0 0 0 0 0 9 3 0 1
Ceftazidim 2 1 6 0 0 1 0 0 0 4 7 2
Ciprofloxacin 6 4 10 4 2 0 0 0 12 3 10 3
Gentamicin 7 4 10 3 0 0 0 0 11 5 5 3
Imipenem 10 8 19 8 0 0 0 0 0 0 0 0
Nitrofurantoine 5 2 5 3 0 0 1 0 1 3 3 2
Ceftriaxone 3 3 5 2 1 0 0 0 16 6 13 4
Total 53 (39.5%) 41 (57.7%) 70 (50.7%) 27 (51.9%) 5 (3.7%) 1 (1.4%) 1 (0.7%) 1 (1.9%) 76 (56.7%) 29 (40.8%) 67 (48.5%) 24 (46.1%)
Proteus
Amikacin 8 4 13 5 0 0 0 0 3 0 1 0
Ampicillin/sulbactam 1 2 11 5 0 0 0 0 0 0 4 0


















Table 3 Comparison of resistance pattern of isolated bacteria against different antimicrobial agents in four-year period (Continued)
Cefepime 1 0 4 1 0 1 0 0 1 2 0 0
Ceftazidim 2 0 8 4 0 1 0 0 2 3 1 0
Ciprofloxacin 4 2 8 6 0 0 0 0 5 3 7 0
Gentamicin 2 5 8 1 1 0 0 0 4 0 0 1
Imipenem 7 6 17 6 0 0 0 0 0 0 0 0
Nitrofurantoine 1 1 0 0 0 0 0 0 2 0 1 1
Ceftriaxone 5 3 14 6 0 0 0 0 5 0 2 0
Piperacillin/ tazobactam 1 1 12 5 0 0 0 0 0 0 0 0
Total 36 (54.5%) 26 (65%) 99 (79.8%) 42 (93.3%) 1 (1.5%) 3 (7.5%) 0 (0) 0 (0) 29 (43.9%) 11 (27.5%) 25 (20.2%) 3 (6.7%)
Pseudomona
Amikacin 9 18 12 11 0 0 0 0 2 3 11 6
Ampicillin/sulbactam 0 0 3 0 0 0 0 0 2 4 20 14
Cotrimoxazole 0 7 4 2 0 0 0 0 13 11 20 14
Cefepime 0 0 2 1 0 0 0 0 1 8 4 3
Ceftazidim 2 0 4 3 0 0 0 0 1 12 12 4
Ciprofloxacin 8 6 10 12 0 1 1 0 2 9 14 3
Gentamicin 5 12 1 4 0 0 0 0 3 7 10 2
Imipenem 9 22 26 15 0 0 0 0 1 0 1 1
Nitrofurantoine 1 0 0 0 0 0 1 0 1 8 3 5
Ceftriaxone 2 2 4 5 0 4 1 0 7 13 19 8
Piperacillin/ tazobactam 1 3 13 6 0 0 0 1 1 0 4 3
Total 37 (52.1%) 70 (46.7%) 79 (39.9%) 59 (48%) 0 (0) 5 (3.3%) 3 (1.6%) 1 (0.8%) 34 (47.9%) 75 (50%) 118 (62.1%) 63 (51.2%)
Stenotrophomonas sp.
Amikacin 9 40 83 25 2 1 0 1 11 31 29 24
Ampicillin/sulbactam 1 1 1 1 1 0 0 1 9 19 5 2
Cotrimoxazole 22 78 107 35 0 0 0 0 1 2 2 10
Cefixime 0 0 0 0 0 0 0 0 12 44 2 9
Cefotaxime 1 0 0 0 2 0 0 0 5 8 3 1
Ceftazidim 0 5 1 2 0 1 0 0 9 31 1 6
Ciprofloxacin 15 39 109 45 0 0 0 0 3 0 0 1
Gentamicin 8 31 3 2 1 2 0 0 4 9 3 0
Imipenem 2 10 2 2 1 1 0 0 20 49 7 9
Ceftriaxone 1 5 3 2 0 0 1 0 16 65 91 49
Piperacillin/ tazobactam 2 3 5 2 0 0 0 0 0 1 1 0
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http://www.darujps.com/content/20/1/28derived pathogen from urine and S. maltophilia from
bloodstream samples. In a similar Korean study, E. coli
had the first rank in terms of the most prevalent organ-
ism isolated, Pseudomona sp., and Klebseilla sp. had the
next ranks among isolated gram-negative pathogens
[15]. During 2000 to 2002, more than 220,000 isolated
were collected from intensive care units of five countries
including France, Germany, Italy, Canada and United
States, in which the most common gram-negative patho-
gen was E. coli followed by Pseudomona sp. [16]. S. mal-
tophilia which was the most common pathogen for
bloodstream samples in the present study, were less
common in western countries, however it was also seen
frequently in Saudi isolates [17].
Antibiotic resistance among Acinetobacter spp., and
Citrobacter spp. were more frequent in comparison
with other isolated pathogens, and our susceptibility
rates were similar to rates reported from other regions
of the world [18,19]. However, the susceptibility rate of
Acinetobacter spp. in our study was less than similar
surveillance five-year study in Children Medical Center
in Iran [20] and was more consistent with reports of
antimicrobial resistance from other parts of the world
[19,21]. Since that Iranian report dated back to ap-
proximately a decade ago, this may demonstrate the in-
crease in the rate of Acinetobacter resistance in Iran
like other countries over the world. Moreover, the re-
sistance frequency rate of Acinetobacter to Ampicillin/
sulbactam had an increasing trend after 2007. This was
because the availability of generic Iranian formulation
of this specific antibiotic in 2007 as well as the admin-
istration of oral dosage forms which was used wide-
spread in that year.
The most commonly administered antibiotics in dif-
ferent countries all over the world are β-lactams, and
decreased susceptibility of nosocomial pathogens to this
therapeutic class of antibiotics has resulted in a major
clinical disaster [22]. Iran is not an exception for this
statement, and cephalosporines are commonly used in
the country because of their availability as well as low
rate of adverse events [12]. With respect to antibiotics,
the most frequent resistance to antibiotics was observed
in ampicillin (66.7-100%) and third generation cepha-
losporines consisting of cefotaxime (57.2-100%), ceftazi-
dim (42.1-86.4%), cefixime (45-75%) and ceftriaxone
(65.7-74.8%). To elucidate the importance of increasing
resistance, it is worth mentioning that even the resist-
ant rate of Enterobacter as the most susceptible micro-
organism to cefixime was increased in a four-year
period. In contrast, the lowest resistant rates were seen
with imipenem (4.5-26.5%),piperacillin/tazobactam (7.9-
22.2%), and amikacin (21.3-33.3%). Resistance to third
generation cephalosporines in this study was higher
than similar studies evaluating the susceptibility rates ofgram-negative pathogens [23-25]. This higher resistance
can be attributed to the frequent use of third gener-
ation cephalosporines in the empirical management of
infectious in Iran as the resistance rate of E.coli to cef-
tazidim was reduced after its administration was
reduced and it was omitted from local protocols of em-
piric treatment for a period of time. Resistance of
microorganisms to Cefepime, as a fourth generation
cephalosporine, had an increasing trend in 2007–2008
but with restrictions in its usage the susceptibility rates
were improved in 2009–2010.In contrast to previous
studies that reported an increase in the resistance rate
to fluoroquinolones [26,27], we found an improving
susceptibility to ciprofloxacin in our study in a four-
year period with Acinetobacter as an exception. This
can be partly explained by the fact that fluoroquino-
lones are not routinely used as an empirical antibiotic
for infectious diseases in Imam Hospital. In the present
study, resistance to ciprofloxacin was 31.6-54.5% that
was less than similar previous evaluation in Argentina
with resistance rate of more than 80% [28]. On the
other hand, the majority of the nosocomial pathogens
from various specimen resources in the present study
were susceptible to imipenem and this was consistent
through the assessment period. As there was a correl-
ation between previous use of fluoroquinolones and
imipenem resistance [29,30], the low administration
rate of ciprofloxacin and as a consequence improved
sensitivity of organisms to this agent can be the reason
behind the susceptibility of most of the organisms to
imipenem. The low resistance rate of isolates to imipe-
nem was also reported in previous Belgian and Polish
studies with 13% and 8% resistant isolated, respectively
[23,25]. In contrast, in Turkish patients resistance to
imipenem was slightly more prevalent than that of our
study [31]. Amikacin was among the most active anti-
microbial agents against isolates with the low resistant
rate of 21.3-33.3%. Studies performed over a long time
period revealed that the increase in resistance to ami-
noglycosides is milder than for any other antimicrobial
agent even with continued administration [32,33].
In conclusion, the finding of the present study revealed
that resistance rate to common antimicrobial agents in
Iran is growing and isolates were susceptible mostly to
broad-spectrum antibiotics including imipenem and
piperacillin/tazobactam. As the antibiotic resources of
developing countries including Iran are limited, periodic
surveillances of antimicrobial resistance patterns play a
vital role in controlling the spread of resistant strains as
well as implementing protocols for halting the process.
Moreover, it is rational to establish a committee for ap-
propriate antibiotic administration to control the use of
antimicrobial agents at the same time of performing sur-
veillance studies for the aim of effective infection
Khalili et al. DARU Journal of Pharmaceutical Sciences 2012, 20:28 Page 11 of 12
http://www.darujps.com/content/20/1/28management. Such surveillance studies could help in
limiting the rate of antimicrobial resistance all over the
world.
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